Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

161
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
161
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

298
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
298
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

172
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
172
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

142
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
142

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Virtual Sustained Tobacco Treatment for Patients With Cancer: A Randomized Controlled Trial (ECOG-ACRIN: EAQ171CD) Within the National Cancer Institute Community Oncology Research Program.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Reply to: PCWG4: A Missed Opportunity to Make Bone-Protective Agents Mandatory for Patients With Bone Metastatic Castration-Resistant Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Patient Engagement With an Electronic Patient-Reported Outcomes Tool Evaluating Hospital Discharge Readiness After Cancer Surgery.

JCO oncology practice·2026
Same author

Timeliness of Prostate Cancer Treatment in Medicare Advantage and Traditional Medicare: More Similarities than Differences?

JCO oncology practice·2026
Same author

Breaking barriers: Opt-out tobacco dependence treatment in oncology care.

Cancer·2026
Same author

Lessons Learned for Improving Trainee Engagement and Utilization of Education and Training Materials for Cancer Research.

Advances in cancer education and quality improvement·2026

Related Experiment Video

Updated: Jan 12, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K

Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate Cancer.

Aaron P Mitchell1,2,3, Andrew Salner4, Paul Palyca5

  • 1Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.

JCO Oncology Practice
|November 3, 2025
PubMed
Summary

Bone-modifying agent overuse is rare in metastatic castration-sensitive prostate cancer (mCSPC). However, appropriate use in metastatic castration-resistant prostate cancer (mCRPC) varies significantly among providers, indicating a need for interventions to improve care.

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

6.5K

Related Experiment Videos

Last Updated: Jan 12, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

6.5K

Area of Science:

  • Oncology
  • Pharmacology
  • Health Services Research

Background:

  • Clinical guidelines recommend bone-modifying agents (BMAs) for metastatic castration-resistant prostate cancer (mCRPC) to prevent skeletal events.
  • Guidelines advise against BMAs for metastatic castration-sensitive prostate cancer (mCSPC) due to lack of proven benefit in this setting.
  • Previous research identified BMA use gaps, but inter-provider variations remain poorly understood.

Purpose of the Study:

  • To assess inter-provider variation in BMA use for prostate cancer with bone metastases.
  • To evaluate BMA overuse in mCSPC and appropriate use in mCRPC.

Main Methods:

  • Multicenter, retrospective cohort study of 153 patients with prostate cancer and bone metastases (2020-2021).
  • Data collected via chart review across three Northeastern US health systems (two community, one academic).
  • Outcomes assessed: BMA overuse in CSPC (before CRPC without comorbid indication) and appropriate use in CRPC (after CRPC emergence).

Main Results:

  • BMA overuse during CSPC was infrequent (16% of 95 assessable patients), with minimal variation (13-21%) across systems.
  • Appropriate BMA use in patients who developed CRPC was 44% (24/55).
  • Significant inter-system variation in appropriate BMA use for mCRPC was observed (22% to 54%).

Conclusions:

  • BMA overuse in mCSPC appears rare, possibly due to de-implementation efforts.
  • Substantial variation exists in appropriate BMA use for mCRPC among clinicians and health systems.
  • Interventions targeting guideline-concordant care are needed to optimize patient outcomes.